Literature DB >> 30522596

Management Options for Irritable Bowel Syndrome.

Michael Camilleri1.   

Abstract

Irritable bowel syndrome (IBS) is associated with diverse pathophysiologic mechanisms. These mechanisms include increased abnormal colonic motility or transit, intestinal or colorectal sensation, increased colonic bile acid concentration, and superficial colonic mucosal inflammation, as well as epithelial barrier dysfunction, neurohormonal up-regulation, and activation of secretory processes in the epithelial layer. Novel approaches to treatment include lifestyle modification, changes in diet, probiotics, and pharmacotherapy directed to the motility, sensation, and intraluminal milieu of patients with IBS. Despite recent advances, there is a need for development of new treatments to relieve pain in IBS without deleterious central or other adverse effects.
Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30522596      PMCID: PMC6314474          DOI: 10.1016/j.mayocp.2018.04.032

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  140 in total

1.  Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors.

Authors:  U Simmen; O Kelber; S N Okpanyi; R Jaeggi; B Bueter; D Weiser
Journal:  Phytomedicine       Date:  2006-09-14       Impact factor: 5.340

Review 2.  A Systematic Review of the Effects of Polyols on Gastrointestinal Health and Irritable Bowel Syndrome.

Authors:  Adrienne Lenhart; William D Chey
Journal:  Adv Nutr       Date:  2017-07-14       Impact factor: 8.701

3.  Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats.

Authors:  T Kamiya; L Wang; P Forsythe; G Goettsche; Y Mao; Y Wang; G Tougas; J Bienenstock
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

4.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Authors:  M Pimentel; E J Chow; H C Lin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

5.  Excitation of rat colonic afferent fibres by 5-HT(3) receptors.

Authors:  Gareth A Hicks; Jonathan R Coldwell; Marcus Schindler; Philip A Bland Ward; David Jenkins; Penny A Lynn; Patrick P A Humphrey; L Ashley Blackshaw
Journal:  J Physiol       Date:  2002-11-01       Impact factor: 5.182

6.  A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function.

Authors:  Maria I Vazquez-Roque; Michael Camilleri; Thomas Smyrk; Joseph A Murray; Eric Marietta; Jessica O'Neill; Paula Carlson; Jesse Lamsam; Denise Janzow; Deborah Eckert; Duane Burton; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2013-01-25       Impact factor: 22.682

7.  Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.

Authors:  John F Johanson; Dan Morton; Joseph Geenen; Ryuji Ueno
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

8.  Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Authors:  M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2014-09-22       Impact factor: 3.598

9.  Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.

Authors:  L A Houghton; C Fell; P J Whorwell; I Jones; D P Sudworth; J D Gale
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

Review 10.  Guidelines on the irritable bowel syndrome: mechanisms and practical management.

Authors:  R Spiller; Q Aziz; F Creed; A Emmanuel; L Houghton; P Hungin; R Jones; D Kumar; G Rubin; N Trudgill; P Whorwell
Journal:  Gut       Date:  2007-05-08       Impact factor: 23.059

View more
  22 in total

1.  Gualou Xiebai Decoction ameliorates increased Caco-2 monolayer permeability induced by bile acids via tight junction regulation, oxidative stress suppression and apoptosis reduction.

Authors:  Jiyuan Su; Zhiqing He; Yunhua Yu; Mingfang Lu; Zonggui Wu; Dongmei Zhang
Journal:  J Bioenerg Biomembr       Date:  2021-10-31       Impact factor: 2.945

2.  Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

Authors:  Anca Trifan; Ovidiu Burta; Nicoleta Tiuca; Diana Corina Petrisor; Augustin Lenghel; Javier Santos
Journal:  United European Gastroenterol J       Date:  2019-07-03       Impact factor: 4.623

3.  Pharmacological Inhibition of the Voltage-Gated Sodium Channel NaV1.7 Alleviates Chronic Visceral Pain in a Rodent Model of Irritable Bowel Syndrome.

Authors:  Yan Jiang; Joel Castro; Linda V Blomster; Akello J Agwa; Jessica Maddern; Gudrun Schober; Volker Herzig; Chun Yuen Chow; Fernanda C Cardoso; Paula Demétrio De Souza França; Junior Gonzales; Christina I Schroeder; Steffen Esche; Thomas Reiner; Stuart M Brierley; Glenn F King
Journal:  ACS Pharmacol Transl Sci       Date:  2021-06-07

4.  The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Tao Bai; Haoyu Zeng; Yanqin Long; Xiaoqing Li; Xiaohong Sun; Yu Lan; Lingling Gao; Lu Zhang; Zenghui Feng; Xiaohua Hou
Journal:  Trials       Date:  2020-06-30       Impact factor: 2.279

Review 5.  The Immunomodulatory Properties of Extracellular Vesicles Derived from Probiotics: A Novel Approach for the Management of Gastrointestinal Diseases.

Authors:  Jose Alberto Molina-Tijeras; Julio Gálvez; Maria Elena Rodríguez-Cabezas
Journal:  Nutrients       Date:  2019-05-09       Impact factor: 5.717

Review 6.  Effectiveness of vitamin D for irritable bowel syndrome: A protocol for a systematic review of randomized controlled trial.

Authors:  Sheng-Mei Shi; Yan-Li Wen; Hai-Bin Hou; Hai-Xia Liu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

7.  Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome.

Authors:  Jeffrey M Lackner; James Jaccard
Journal:  J Consult Clin Psychol       Date:  2021-05

8.  Motility index measured by magnetic resonance enterography is associated with sex and mural thickness.

Authors:  Sven Månsson; Olle Ekberg; Bodil Ohlsson
Journal:  World J Gastroenterol       Date:  2020-09-28       Impact factor: 5.742

9.  Evaluation of the short-term efficacy of local analgesic (lidocaine) and opioid analgesic (sufentanil) on patients with centrally mediated abdominal pain syndrome: a randomized controlled trial.

Authors:  Hang Yang; Honglin Chen; Bing Hu
Journal:  Therap Adv Gastroenterol       Date:  2021-06-24       Impact factor: 4.409

10.  IBS Patients' Treatment Expectancy and Motivation Impacts Quality of the Therapeutic Alliance With Provider: Results of the IBS Outcome Study.

Authors:  Jeffrey M Lackner; Brian M Quigley; Christopher D Radziwon; Alison M Vargovich
Journal:  J Clin Gastroenterol       Date:  2021 May-Jun 01       Impact factor: 3.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.